• A sponsored session will feature Dr. Alex Hastie from Bionano, Dr. Suk See De Ravin from National Institute of Health (NIH) and Travis Hardcastle from Synthego presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applications

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the International Society for Stem Cell Research (ISSCR) Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping (OGM) for research, development, and manufacturing applications in stem cell therapy. ISSCR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine. The ISSCR conference will be held June 14-17, 2023, online and in-person in Boston, Massachusetts.

As part of a sponsored session titled “Optical Genome Mapping - Redefining Cell Line Genomic Integrity and Off-target Characterization,” three experts will share their experiences using OGM in their research, development and manufacturing processes. Presentations will cover OGM’s utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing. Dr. Alex Hastie (Bionano), Dr. Suk See De Ravin from National Institute of Health (NIH) and Travis Hardcastle from Synthego will present in Room 255 on Friday, June 16, 2023, at 11:30 am ET.

A scientific poster by Dr. Andy Pang from Bionano, covering the use of OGM in cell manufacturing and bioprocessing applications, will be on display during the conference.

“We are excited to participate in ISSCR’s annual meeting and to see content that demonstrates OGM’s utility for pharmaceutical research and drug development. We believe that OGM can play a significant role in the development of new methods to analyze the quality of genome-edited cells, and welcome discussion of its incorporation into cell bioprocessing workflows, including stem cell therapy,” commented Erik Holmlin, president and chief executive officer of Bionano.

More details on the conference can be found here: https://bionano.com/isscr2023/.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.

Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility in research, development, and manufacturing processes for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing, ; the utility of OGM for research in the areas reported in the presentations given and the posters made available at ISSCR’s annual meeting, and the growth and adoption of OGM for use in monitoring genomic integrity and off-target effects in cell lines. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, the impact of the COVID-19 pandemic and the ongoing Ukraine-Russian conflict and related sanctions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing; failure of OGM to be used or prove useful for monitoring genomic integrity and off-target effects in cell lines; failure of researchers to adopt OGM; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ISSCR’s annual meeting; future study results contradicting the results reported in the presentations given and posters made available at the ISSCR’s annual meeting; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
This email address is being protected from spambots. You need JavaScript enabled to view it.